Absci ABSI
NASDAQ ABSI
$11.09 +0.92 (+9.05%)
As of: Nov 9, 2026 · 10:44 AM EST

Absci (ABSI) Gains from Sales and Divestitures (2020 - 2021)

Updated

Absci's Gains from Sales and Divestitures was -$931,000 in Q4 2021, compared with -$319,000 a year earlier.

Analysis

Absci (ABSI) Gains from Sales and Divestitures (2020 - 2021) Analysis & Trends

For FY2021, Gains from Sales and Divestitures at Absci came in at -$948,000.

  • In earlier years, Gains from Sales and Divestitures was -$363,000 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,248.16 Bn 1,221.78 Bn 20.46 Bn
2 Johnson & Johnson 670.28 Bn 590.14 Bn 17.30 Bn
3 AbbVie 514.81 Bn 482.82 Bn 13.12 Bn
4 Merck 363.68 Bn 326.63 Bn 13.19 Bn
5 Novartis Ag 314.66 Bn 287.90 Bn -
6 Astrazeneca 292.36 Bn 266.25 Bn 13.26 Bn
7 Amgen 248.52 Bn 200.18 Bn 7.58 Bn
8 Gilead Sciences 209.74 Bn 184.85 Bn 6.73 Bn
9 Pfizer 165.67 Bn 113.03 Bn 12.56 Bn
10 Absci 1.74 Bn 1.12 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -931,000.00
Sep 30, 2021 -17,000.00
Dec 31, 2020 -319,000.00
Sep 30, 2020 -42,000.00
API Access

Absci Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ABSI&period=max&api_key=YOUR_API_KEY